Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial

Tymon Pol, Claes Held, Johan Westerbergh, Johan Lindbäck, John H Alexander, Marco Alings, Cetin Erol, Shinya Goto, Sigrun Halvorsen, Kurt Huber, Michael Hanna, Renato D Lopes, Witold Ruzyllo, Christopher B Granger, Ziad Hijazi, Tymon Pol, Claes Held, Johan Westerbergh, Johan Lindbäck, John H Alexander, Marco Alings, Cetin Erol, Shinya Goto, Sigrun Halvorsen, Kurt Huber, Michael Hanna, Renato D Lopes, Witold Ruzyllo, Christopher B Granger, Ziad Hijazi

Abstract

Background: Dyslipidemia is a major risk factor for cardiovascular events. The prognostic importance of lipoproteins in patients with atrial fibrillation is not well understood. We aimed to explore the association between apolipoprotein A1 (ApoA1) and B (ApoB) and cardiovascular events in patients with atrial fibrillation receiving oral anticoagulation.

Methods and results: Using data from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial, ApoA1 and ApoB plasma levels were measured at baseline in 14 884 atrial fibrillation patients. Median length of follow-up was 1.9 years. Relationships between continuous levels of ApoA1 and ApoB and clinical outcomes were evaluated using Cox models adjusted for cardiovascular risk factors, medication including statins, and cardiovascular biomarkers. A composite ischemic outcome (ischemic stroke, systemic embolism, myocardial infarction, and cardiovascular death) was used as the primary end point. Median (25th, 75th) ApoA1 and ApoB levels were 1.10 (0.93, 1.30) and 0.70 g/L (0.55, 0.85), respectively. In adjusted analyses, higher levels of ApoA1 were independently associated with a lower risk of the composite ischemic outcome (hazard ratio, 0.81; P<0.0001). Similar results were observed for the individual components of the composite outcome. ApoB was not significantly associated with the composite ischemic outcome (P=0.8240). Neither apolipoprotein was significantly associated with major bleeding. There was no interaction between lipoproteins and randomized treatment for the primary outcome (both P values ≥0.2448).

Conclusions: In patients with atrial fibrillation on oral anticoagulation, higher levels of ApoA1 were independently associated with lower risk of ischemic cardiovascular outcomes. Investigating therapies targeting dyslipidemia may thus be useful to improve cardiovascular outcomes in patients with atrial fibrillation.

Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00412984.

Keywords: atrial fibrillation; biomarkers; cardiovascular disease; cerebrovascular disease/stroke.

© 2018 The Authors and Bristol‐Myers Squibb. Published on behalf of the American Heart Association, Inc., by Wiley.

Figures

Figure 1
Figure 1
Cumulative hazard rates for the composite ischemic outcome by quartiles of ApoA1. ApoA1 indicates apolipoprotein A1; Q, quartile.
Figure 2
Figure 2
Cumulative hazard rates for the composite ischemic outcome by quartiles of ApoB. ApoB indicates apolipoprotein B; Q, quartile.
Figure 3
Figure 3
One‐year event rates for continuous level of ApoA1 according to randomized treatment. ApoA1 indicates apolipoprotein A1; Cardiac dth, cardiac death; MI, myocardial infarction; SEE, systemic embolic event.
Figure 4
Figure 4
One‐year event rates for continuous level of ApoB according to randomized treatment. ApoB indicates apolipoprotein B; Cardiac dth, cardiac death; MI, myocardial infarction; SEE, systemic embolic event.

References

    1. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946–952.
    1. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim YH, McAnulty JH Jr, Zheng ZJ, Forouzanfar MH, Naghavi M, Mensah GA, Ezzati M, Murray CJ. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129:837–847.
    1. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893–2962.
    1. Hijazi Z, Oldgren J, Siegbahn A, Wallentin L. Application of biomarkers for risk stratification in patients with atrial fibrillation. Clin Chem. 2017;63:152–164.
    1. Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Alexander JH, Atar D, Gersh BJ, Hanna M, Harjola VP, Horowitz JD, Husted S, Hylek EM, Lopes RD, McMurray JJ, Granger CB. High‐sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. J Am Coll Cardiol. 2014;63:52–61.
    1. Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Christersson C, Ezekowitz J, Gersh BJ, Hanna M, Hohnloser S, Horowitz J, Huber K, Hylek EM, Lopes RD, McMurray JJ, Granger CB. N‐terminal pro‐B‐type natriuretic peptide for risk assessment in patients with atrial fibrillation. J Am Coll Cardiol. 2013;61:2274–2284.
    1. Wallentin L, Hijazi Z, Andersson U, Alexander JH, De Caterina R, Hanna M, Horowitz JD, Hylek EM, Lopes RD, Asberg S, Granger CB, Siegbahn A. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2014;130:1847–1858.
    1. Wong N D. Epidemiological studies of CHD and the evolution of preventive cardiology. Nat Rev Cardiol. 2014;11:276–289.
    1. Scandinavian Simvastatin Survival Study Group . Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389.
    1. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, Watson AD, Lusis AJ. Atherosclerosis: basic mechanisms oxidation, inflammation, and genetics. Circulation. 1995;91:2488–2496.
    1. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62:707–714.
    1. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Borén J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR, Tokgözoglu L, Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ, Catapano AL. Low‐density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38:2459–2472.
    1. Yaghi S, Elkind MS. Lipids and cerebrovascular disease. Stroke. 2015;46:3322–3328.
    1. Hijazi Z, Aulin J, Andersson U, Alexander JH, Gersh B, Granger CB, Hanna M, Horowitz J, Hylek EM, Lopes RD, Siegbahn A, Wallentin L; ARISTOTLE Investigators . Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. Heart. 2016;102:508–517.
    1. Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, Keltai M, Lanas F, Lopes RD, Lopez‐Sendon J, Granger CB, Wallentin L. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012;33:2821–2830.
    1. Lopes RD, Alexander JH, Al‐Khatib SM, Ansell J, Diaz R, Easton JD, Gersh BJ, Granger CB, Hanna M, Horowitz J, Hylek EM, McMurray JJ, Verheugt FW, Wallentin L; ARISTOTLE Investigators . Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010;159:331–339.
    1. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al‐Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez‐Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators . Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–992.
    1. Hijazi Z, Siegbahn A, Andersson U, Granger CB, Alexander JH, Atar D, Gersh BJ, Mohan P, Harjola VP, Horowitz J, Husted S, Hylek EM, Lopes RD, McMurray JJ, Wallentin L; ARISTOTLE Investigators . High‐sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2014;129:625–634.
    1. Harrell FE Jr. Regression Modeling Strategies, With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis, 2nd ed New York, NY: Springer; 2015.
    1. Kim SM, Kim JM, Shin DG, Kim JR, Cho KH. Relation of atrial fibrillation (AF) and change of lipoproteins: male patients with AF exhibited severe pro‐inflammatory and pro‐atherogenic properties in lipoproteins. Clin Biochem. 2014;47:869–875.
    1. Alonso A, Yin X, Roetker NS, Magnani JW, Kronmal RA, Ellinor PT, Chen LY, Lubitz SA, McClelland RL, McManus DD, Soliman EZ, Huxley RR, Nazarian S, Szklo M, Heckbert SR, Benjamin EJ. Blood lipids and the incidence of atrial fibrillation: the Multi‐Ethnic Study of Atherosclerosis and the Framingham Heart Study. J Am Heart Assoc. 2014;3:e001211 DOI: .
    1. Lopez FL, Agarwal SK, Maclehose RF, Soliman EZ, Sharrett AR, Huxley RR, Konety S, Ballantyne CM, Alonso A. Blood lipid levels, lipid‐lowering medications, and the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities study. Circ Arrhythm Electrophysiol. 2012;5:155–162.
    1. Watanabe H, Tanabe N, Yagihara N, Watanabe T, Aizawa Y, Kodama M. Association between lipid profile and risk of atrial fibrillation. Circulation. 2011;75:2767–2774.
    1. Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, White R, Furberg CD, Rautaharju PM. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997;96:2455–2461.
    1. Mora S, Akinkuolie AO, Sandhu RK, Conen D, Albert CM. Paradoxical association of lipoprotein measures with incident atrial fibrillation. Circ Arrhythm Electrophysiol. 2014;7:612–619.
    1. Norby FL, Eryd SA, Niemeijer MN, Rose LM, Smith AV, Yin X, Agarwal SK, Arking DE, Chasman DL, Chen LY, Eijgelsheim M, Engstrom G, Franco OH, Heeringa J, Hindy G, Hofman A, Lutsey PL, Magnani JW, McManus DD, Orho‐Melander M, Pankow JS, Rukh G, Schulz CA, Uitterlinden AG, Albert CM, Benjamin EJ, Gudnason V, Smith JG, Stricker BH, Alonso A. Association of lipid‐related genetic variants with the incidence of atrial fibrillation: the AFGen consortium. PLoS One. 2016;11:e0151932.
    1. Krauss RM. Triglycerides and atherogenic lipoproteins: rationale for lipid management. Am J Med. 1998;105:58S–62S.
    1. Grundy SM, Small LDL. Atherogenic dyslipidemia, and the metabolic syndrome. Circulation. 1997;95:1–4.
    1. Francis GA, Perry RJ. Targeting HDL‐mediated cellular cholesterol efflux for the treatment and prevention of atherosclerosis. Clin Chim Acta. 1999;286:219–230.
    1. Mackness MI, Durrington PN. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis. 1995;115:243–253.
    1. Reddy VS, Bui QT, Jacobs JR, Begelman SM, Miller DP, French WJ. Relationship between serum low‐density lipoprotein cholesterol and in‐hospital mortality following acute myocardial infarction (the lipid paradox). Am J Cardiol. 2015;115:557–562.
    1. Schupf N, Costa R, Luchsinger J, Tang MX, Lee JH, Mayeux R. Relationship between plasma lipids and all‐cause mortality in nondemented elderly. J Am Geriatr Soc. 2005;53:219–226.
    1. Rosenson RS. Myocardial injury: the acute phase response and lipoprotein metabolism. J Am Coll Cardiol. 1993;22:933–940.
    1. Weverling‐Rijnsburger AW, Blauw GJ, Lagaay AM, Knook DL, Meinders AE, Westendorp RG. Total cholesterol and risk of mortality in the oldest old. Lancet. 1997;350:1119–1123.
    1. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, Tracy RP, Powe NR, Klag MJ. Association between cholesterol level and mortality in dialysis patients. JAMA. 2004;291:451–459.
    1. Jungner I, Marcovina SM, Walldius G, Holme I, Kolar W, Steiner E. Apolipoprotein B and A‐I values in 147576 Swedish males and females, standardized according to the World Health Organization‐International Federation of Clinical Chemistry First International Reference Materials. Clin Chem. 1998;44:1641–1649.
    1. Wang X, Dong Y, Qi X, Huang C, Hou L. Cholesterol levels and risk of hemorrhagic stroke: a systematic review and meta‐analysis. Stroke. 2013;44:1833–1839.
    1. Qi Z, Chen H, Wen Z, Yuan F, Ni H, Gao W, Shen J, Li J, Lin Y, Shan Y, Jin B, Yan P, Shi H, Luo X. Relation of low‐density lipoprotein cholesterol to ischemic stroke in patients with nonvalvular atrial fibrillation. Am J Cardiol. 2017;119:1224–1228.
    1. Ruff CT, Giugliano RP, Braunwald E, Murphy SA, Brown K, Jarolim P, Mercuri M, Antman EM, Morrow DA. Cardiovascular biomarker score and clinical outcomes in patients with atrial fibrillation: a subanalysis of the ENGAGE AF‐TIMI 48 randomized clinical trial. JAMA Cardiol. 2016;1:999–1006.
    1. Hijazi Z, Oldgren J, Lindbäck J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Granger CB, Wallentin L. The novel biomarker‐based ABC (age, biomarkers, clinical history)‐bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet. 2016;387:2302–2311.
    1. Hijazi Z, Lindbäck J, Alexander JH, Hanna M, Held C, Hylek EM, Lopes RD, Oldgren J, Siegbahn A, Stewart RA, White HD, Granger CB, Wallentin L. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker‐based risk score for predicting stroke in atrial fibrillation. Eur Heart J. 2016;37:1582–1590.
    1. Keene D, Price C, Shun‐Shin MJ, Francis DP. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta‐analysis of randomised controlled trials including 117,411 patients. BMJ. 2014;349:g4379.
    1. Kaur N, Pandey A, Negi H, Shafiq N, Reddy S, Kaur H, Chadha N, Malhotra S. Effect of HDL‐raising drugs on cardiovascular outcomes: a systematic review and meta‐regression. PLoS One. 2014;9:e94585.
    1. Group HTRC , Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, Wiviott SD, Cannon CP, Braunwald E, Sammons E, Landray MJ. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377:1217–1227.
    1. Tardif JC, Rhéaume E, Lemieux Perreault LP, Grégoire JC, Feroz Zada Y, Asselin G, Provost S, Barhdadi A, Rhainds D, L'Allier PL, Ibrahim R, Upmanyu R, Niesor EJ, Benghozi R, Suchankova G, Laghrissi‐Thode F, Guertin MC, Olsson AG, Mongrain I, Schwartz GG, Dubé MP. Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib. Circ Cardiovasc Genet. 2015;8:372–382.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa